Ani Pharmaceuticals (ANIP) Shares Outstanding (Weighted Average) (2010 - 2026)

Ani Pharmaceuticals has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $20.9 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $20.9 million, up 6.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.9 million (up 6.67% YoY), and the FY2025 annual result was $20.1 million, up 3.8% from the prior year.
• Shares Outstanding (Weighted Average) came in at $20.9 million for Q1 2026 at Ani Pharmaceuticals, up from $20.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $20.9 million in Q1 2026 to a low of $16.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $19.1 million (2024), against an average of $18.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 35.12% in 2022 and rose 1.58% in 2023, its largest moves.
• Ani Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $16.3 million in 2022, then grew by 10.71% to $18.0 million in 2023, then climbed by 7.32% to $19.3 million in 2024, then climbed by 3.8% to $20.1 million in 2025, then climbed by 4.29% to $20.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $20.9 million (Q1 2026), $20.1 million (Q4 2025), and $19.8 million (Q3 2025), per Business Quant data.